{
  "id": "Ex012",
  "type": "Example",
  "informationId": {
    "id": "CritAssess286",
    "type": "CriterionAssessment",
    "criterion": {
      "id": "Crit306",
      "type": "Criterion",
      "label": "PS3",
      "description": "Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product",
      "defaultStrength": {
        "id": "EvLnStrgID145",
        "type": "EvidenceLineStrength",
        "label": "Pathogenic Strong"
      },
      "comments": "This particular rule will probably be downgraded often, given that there are not many “Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting”"
    },
    "variant": {
      "id": "CanAll020",
      "type": "CanonicalAllele",
      "preferredCtxAllele": {
        "id": "CtxAll023",
        "type": "ContextualAllele",
        "relatedCanonicalAllele": "CanAll020",
        "alleleName": "NM_004333.4(BRAF):c.1787G>T",
        "produces": [
          {
            "id": "CtxAll024",
            "type": "ContextualAllele",
            "relatedCanonicalAllele": "CanAll021",
            "alleleName": "NP_004324.2:p.Gly596Val",
            "producedBy": "CtxAll023"
          }
        ]
      }
    },
    "outcome": {
      "id": "CritEvalID074",
      "type": "CriterionEvaluation",
      "label": "Met"
    },
    "evidenceLine": [
      {
        "id": "EvLn017",
        "type": "EvidenceLine",
        "evidenceItem": [
          {
            "id": "Func026",
            "type": "AlleleFunctionalImpact",
            "resultDescription": "abnormal/deceased MEK activtation.",
            "assayType": {
              "id": "AFAMID076",
              "type": "AlleleFunctionalAssayMethod",
              "label": "Activation Assay"
            },
            "contextualAllele": {
              "id": "CtxAll024",
              "type": "ContextualAllele",
              "relatedCanonicalAllele": "CanAll021",
              "alleleName": "NP_004324.2:p.Gly596Val",
              "producedBy": "CtxAll023"
            },
            "gene": {
              "id": "G240",
              "type": "Gene",
              "geneSymbol": "MEK"
            }
          }
        ]
      },
      {
        "id": "EvLn018",
        "type": "EvidenceLine",
        "evidenceItem": [
          {
            "id": "Func027",
            "type": "AlleleFunctionalImpact",
            "resultDescription": "abnormal/deceased ERK activtation.",
            "assayType": {
              "id": "AFAMID076",
              "type": "AlleleFunctionalAssayMethod",
              "label": "Activation Assay"
            },
            "contextualAllele": {
              "id": "CtxAll024",
              "type": "ContextualAllele",
              "relatedCanonicalAllele": "CanAll021",
              "alleleName": "NP_004324.2:p.Gly596Val",
              "producedBy": "CtxAll023"
            },
            "gene": {
              "id": "G241",
              "type": "Gene",
              "geneSymbol": "ERK"
            }
          }
        ]
      }
    ],
    "contribution": [
      {
        "type": "Contribution",
        "agent": {
          "id": "Agent001",
          "type": "Agent",
          "label": "Harry Stevenson"
        },
        "contributionDate": "6/4/16 7:12 AM",
        "contributionRole": {
          "id": "ContribRoleID193",
          "type": "ContributoryRole",
          "label": "assessor role"
        }
      },
      {
        "type": "Contribution",
        "agent": {
          "id": "Agent002",
          "type": "Agent",
          "label": "Noonan/Rasopathy WG (ClinGen)"
        },
        "contributionDate": "6/4/16 7:12 AM",
        "contributionRole": {
          "id": "ContribRoleID193",
          "type": "ContributoryRole",
          "label": "assessor role"
        }
      }
    ],
    "description": "The RASopathy group considers MEK and ERK activation assays as well validated."
  },
  "index": 3,
  "author": "Steven Harrison",
  "description": "Assessed variant: NM_004333.4(BRAF):c.1787G>T (p.Gly596Val)  \nThe RASopathy group decided for BRAF both MEK activation and ERK activation assays (in which the variant results in abnormal pattern of pERK/ERK or pMEK/MEK) is a validated assay.\nPMID:16439621 shows that Gly596Val results in abnormal/decreased MEK and ERK activiation so PS3 is applicable for this variant "
}
